1. Home
  2. WST vs ILMN Comparison

WST vs ILMN Comparison

Compare WST & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Pharmaceutical Services Inc.

WST

West Pharmaceutical Services Inc.

HOLD

Current Price

$248.49

Market Cap

16.6B

Sector

Health Care

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$120.37

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WST
ILMN
Founded
1923
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6B
20.4B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
WST
ILMN
Price
$248.49
$120.37
Analyst Decision
Buy
Hold
Analyst Count
7
17
Target Price
$328.00
$125.12
AVG Volume (30 Days)
1.1M
2.3M
Earning Date
02-12-2026
02-05-2026
Dividend Yield
0.35%
N/A
EPS Growth
0.17
N/A
EPS
6.75
5.45
Revenue
$3,017,900,000.00
$4,343,000,000.00
Revenue This Year
$6.97
$3.50
Revenue Next Year
$6.27
$6.30
P/E Ratio
$36.87
$21.97
Revenue Growth
4.92
N/A
52 Week Low
$187.43
$68.70
52 Week High
$335.20
$155.53

Technical Indicators

Market Signals
Indicator
WST
ILMN
Relative Strength Index (RSI) 38.53 31.38
Support Level $229.97 $147.57
Resistance Level $241.38 $153.48
Average True Range (ATR) 8.06 5.28
MACD -0.76 -3.12
Stochastic Oscillator 33.74 5.52

Price Performance

Historical Comparison
WST
ILMN

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: